flâneur

Topos Bio – Redefining Druggable Space

toposbio.ai · 137 words · saved by 1 readers

Our mission is to unlock a vast, untapped class of disease-relevant targets: Intrinsically Disordered Proteins (IDPs). These proteins, which lack stable structure under physiological conditions, comprise at least 30% of the human proteome and play key roles in a wide array of diseases, including neurodegenerative disorders, cancer, and metabolic dysfunction. Despite their relevance, IDPs have remained largely intractable to traditional drug discovery due to their structural plasticity and the inadequacy of conventional structure-based design tools. Recent advances in AI, such as AlphaFold, have made enormous progress in modeling structured proteins, but these tools fall short when applied to IDPs, which often exist as dynamic ensembles rather than adopting a single defined conformation. Our platform is purpose-built to address this gap. We’ve developed a proprietary AI-enabled discovery engine that integrates biophysics-informed modeling, deep generative design, and high-throughput exp

Topos Bio: Drug Design for Biology in Motion Topos is building an AI-native drug discovery platform for intrinsically disordered proteins -- dynamic proteins implicated in diseases like Alzheimer's and prostate cancer. Our approach models protein ensembles rather than single static structures, unlocking previously "undruggable" targets. Learn More Introducing Topos-1 JAN 08, 2026 Today we're releasing the first technical report on Topos-1, our all-atom foundation model for intrinsically disordered proteins (IDPs). Topos-1 generates physically realistic conformational ensembles for…

saved by

related reading